CD38 - Revision history

John at 19:43, 4 July 2023

2023-07-04T19:43:52Z

← Older revision		Revision as of 21:43, 4 July 2023
Line 53:		Line 53:
	\|-		\|-
	!colspan="8"\|'''Expression in mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%*		\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%*
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%

John at 11:10, 3 July 2023

2023-07-03T11:10:32Z

← Older revision		Revision as of 13:10, 3 July 2023
Line 32:		Line 32:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|~~<span style="font-size:100%">~~'''Expression in primitive cell types'''</font>		!colspan="8"\|'''Expression in primitive cell types'''</font>
	\|-		\|- <span style="font-size:70%">
	! AML !! CMML !! B ALL !! ~~Burkitt~~ \|\| T ALL !! ETP ALL ~~<'''[[ETP ALL\|I]]'''>~~ !! ~~MPAL <'''[[~~MPAL~~\|I]]'''>~~ \|\| ~~Hgns~~ <~~'''[[Hgns\|I]]'''~~>		!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%*		\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%*
	\|style="width: 12.5%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%

John at 08:52, 8 May 2023

2023-05-08T08:52:09Z

← Older revision		Revision as of 10:52, 8 May 2023
Line 77:		Line 77:
	! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL		! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
	\|-		\|-
	\|style="width: 14.25%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 14.25%; background: #~~E6FAFF~~; color:~~black~~"\|<5%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|-		\|-
	\|}		\|}

John at 08:48, 8 May 2023

2023-05-08T08:48:27Z

← Older revision		Revision as of 10:48, 8 May 2023
Line 15:		Line 15:

	<span style="color:navy">'''Normal expression and function'''</span>		<span style="color:navy">'''Normal expression and function'''</span>


	The wide expression of CD38 limits its diagnostic value except in very specific circumstances:		The wide expression of CD38 limits its diagnostic value except in very specific circumstances:
	*The co-expression of CD38 with CD138 can identify normal or neoplastic plasma cells		*The co-expression of CD38 with CD138 can identify normal or neoplastic plasma cells
	*Expression of CD38 in chronic lymphocytic leukaemia (>20% of cells) may associated with poorer outcome		*Expression of CD38 in chronic lymphocytic leukaemia (>20% of cells) may associated with poorer outcome



Line 30:		Line 28:

	----		----


	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-

John at 08:47, 8 May 2023

2023-05-08T08:47:50Z

← Older revision		Revision as of 10:47, 8 May 2023
Line 10:		Line 10:

	</div>		</div>



Line 21:		Line 22:


	<span style="color:navy">'''Other relevant information:'''</span> CD38 is a therapeutic target, daratumumab is a monoclonal antibody which binds to CD38 and is used in the treatment of myeloma.

			<span style="color:navy">'''Other relevant information:'''</span>

			CD38 is a therapeutic target, daratumumab is a monoclonal antibody which binds to CD38 and is used in the treatment of myeloma.

John at 08:47, 8 May 2023

2023-05-08T08:47:20Z

← Older revision		Revision as of 10:47, 8 May 2023
Line 12:		Line 12:


	<span style="color:navy">'''~~What is its diagnostic role?~~'''</span>
			<span style="color:navy">'''Normal expression and function'''</span>


	The wide expression of CD38 limits its diagnostic value except in very specific circumstances:		The wide expression of CD38 limits its diagnostic value except in very specific circumstances:

John at 08:46, 8 May 2023

2023-05-08T08:46:47Z

← Older revision		Revision as of 10:46, 8 May 2023
Line 9:		Line 9:


	</~~span~~>		</div>

John at 08:46, 8 May 2023

2023-05-08T08:46:28Z

← Older revision		Revision as of 10:46, 8 May 2023
Line 1:		Line 1:

			<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;">


	<span style="color:navy">'''~~''DETAILS''~~'''</span>		:<span style="color:navy">'''Summary'''</span>

	CD38 helps mobilise intracellular calcium to activate a wide array of cell functions. In haematological cell types CD38 it is widely expressed by lymphoid cells )B, T and NK) as well as myeloid precursor cells and mature myeloid cells. It has particular diagnostic importance for lymphocytes where CD38 expression is acquired as stem cells commit to B-cell lineage, then is lost as mature B cells emerge from bone marrow before being re-acquired at the time of plasma cell differentiation.		:CD38 helps mobilise intracellular calcium to activate a wide array of cell functions. In haematological cell types CD38 it is widely expressed by lymphoid cells B, T and NK) as well as myeloid precursor cells and mature myeloid cells.
			:CD38 has particular diagnostic importance for lymphocytes where CD38 expression is acquired as stem cells commit to B-cell lineage, then is lost as mature B cells emerge from bone marrow before being re-acquired at the time of plasma cell differentiation.


			</span>

John at 08:43, 8 May 2023

2023-05-08T08:43:41Z

← Older revision		Revision as of 10:43, 8 May 2023
Line 76:		Line 76:

	----		----


	~~<span style="color:navy">'''''SUMMARY TABLES'''''</span>~~

	~~{\| class=wikitable style="text-align: center; width: 800px;"~~

	\|-
	~~!colspan="8"\|Expression of CD38 by primitive lymphoid cells: ALL and haematogones~~
	\|-
	~~! pro-B ALL !! early pre-B ALL !!pre-B ALL!! B-ALL !!pro-T ALL !!mature-T ALL !!AML !!Haematogones~~
	\|-
	~~\|style= "width: 100px; height: 20px; background: #006699; color:white"\|~~
	~~\|style="width: 100px; background: #006699; color:white"\|~~
	~~\|style="width: 100px; background: #006699; color:white"\|~~
	~~\|style="width: 100px; background: #006699; color:white"\|~~
	~~\|style="width: 100px; background: #006699; color:black"\|~~
	~~\|style="width: 100px; background: #006699; color:black"\|~~
	\|style="width: 100px; background: #00b8e6; color:white"\|*
	~~\|style="width: 100px; background: #004466; color:white"\|stg~~
	\|-
	\|}
	~~<span style="font-size:80%">''* low expression correlates with subtype e.g. APML''</span>~~

	~~{\| class=wikitable style="text-align: center; width: 800px; height 20px;"~~

	\|-
	~~!colspan="8"\|Expression of CD38 by mature B cells: B-lymphoproliferative disorders~~
	\|-
	~~! CLL !! MCL !!FL!! HCL !!HCv !!MZL!!LPL!!PCL~~
	\|-
	\|style= "width: 100px; background: #00b8e6; color:black"\|*
	~~\|style="width: 100px; background: #004466; color:white"\|~~
	\|style="width: 100px; background: #004466; color:white"\|**
	~~\|style= "width: 100px; background: #00b8e6; color:white"\|~~
	~~\|style= "width: 100px; background: #00b8e6; color:white"\|~~
	~~\|style="width: 100px; background: #004466; color:white"\|~~
	~~\|style="width: 100px; background: #006699; color:white"\|~~
	~~\|style="width: 100px; background: #004466; color:white"\|stg/mod~~
	\|-
	\|}
	~~<span style="font-size:80%">''*May indicate adverse prognostic when present on more than 20% of cells''</span>~~

	~~<span style="font-size:80%">''**May be weak''</span>~~

	~~----~~

	~~<span style="font-size:80%">'''''1. Colour key:''''' ''- the likelihood of any individual case expressing this marker, indicated by colour:''~~
	~~</span>~~
	~~{\| class=wikitable style="text-align: center; font-size:80%; width: 600px; height: 20px;~~
	\|-
	~~\|style= "background: #E6FAFF; \|Rare (<5%)~~
	~~\|style="background: #66e0ff;"\|Possible (5-20%)~~
	~~\|style="background: #00b8e6;"\|Likely (20-40%)~~
	~~\|style="background: #006699; color:white"\|Frequent (40-80%)~~
	~~\|style="background: #004466; color:white"\|Expected (80-100%)~~
	\|-
	\|}

	~~<span style="font-size:80%">~~
	~~'''''2. Text key''''': - ''where expression level is characteristic of a disorder this is indicated by text:''~~
	~~</span>~~

	~~<span style="font-size:80%">~~
	~~'''abs''' = absent expression, '''wk''' = weak expression, '''mod''' = moderate expression, '''stg''' = strong expression, '''sub''' = expression may be on a sub-population of cells''~~
	~~</span>~~

John at 08:43, 8 May 2023

2023-05-08T08:43:18Z

← Older revision		Revision as of 10:43, 8 May 2023
Line 45:		Line 45:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
	\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%		\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%*
			\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%		\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%
	~~\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%~~		\|style="width: 12.5%; background: #004466; color:white"\|80-100%*
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%**
	\|-		\|-
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' ~~Low~~ level ~~expression has been reported on activated lymphocytes~~, ~~but it has no definite diagnostic role~~ </span>		<span style="font-size:90%">'''Notes:''' Expression level in CLL and DLBCL may have prognostic value, plasma cells express the marker fairly consistently although the levels can vary. </span>

← Older revision		Revision as of 10:43, 8 May 2023
Line 45:		Line 45:
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-
	\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%		\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%*
			\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%		\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%
	~~\|style="width: 12.5%; background: #00b8e6; color:black"\|2-20%~~		\|style="width: 12.5%; background: #004466; color:white"\|80-100%*
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%
	\|style="width: 12.5%; background: #006699; color:white"\|40-80%		\|style="width: 12.5%; background: #006699; color:white"\|40-80%
	\|style="width: 12.5%; background: #004466; color:white"\|80-100%		\|style="width: 12.5%; background: #004466; color:white"\|80-100%**
	\|-		\|-
	\|}		\|}

	<span style="font-size:90%">'''Notes:''' ~~Low~~ level ~~expression has been reported on activated lymphocytes~~, ~~but it has no definite diagnostic role~~ </span>		<span style="font-size:90%">'''Notes:''' Expression level in CLL and DLBCL may have prognostic value, plasma cells express the marker fairly consistently although the levels can vary. </span>